RMOC briefing on adalimumab – May 2018

This second briefing paper is provided through the RMOC system.  It forms the May edition of an expected monthly series of briefings on best value biological medicines.  The briefing summarises: advice on the next steps for commissioners and providers; practical advice in the context of homecare services; and progress to date in planning for the patent expiry of the originator adalimumab product Humira® in October 2018.  In addition, a clinical briefing sheet is provided as well as an adalimumab homecare patient record form.

AdalimumabBiosimilar medicineNewsRMOC medicines optimisation recommendations and resourcesRMOC recommendations and resources

Attachments